Amanda Lewis, PhD

Amanda M. Lewis, PhD is the Site Quality Head for Moderna’s Individualized Neoantigen Therapy (INT) program, where she leads a 90+ person Quality organization supporting clinical manufacturing of patient-specific oncology therapies. Prior to Moderna, Amanda spent a decade at Bristol Myers Squibb in roles of increasing responsibility across technical and quality functions, including leadership of commercial biologics manufacturing science, process validation, and QA. She has been recognized with multiple industry honors, including the Healthcare Businesswomen’s Association Rising Star Award and the Martin Sinacore Outstanding Young Investigator Award. Amanda holds a PhD in Chemical Engineering from the University of Texas at Austin and a BS in Chemical Engineering from MIT.